Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Plus Therapeutics Inc (PSTV)

Plus Therapeutics Inc (PSTV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,725
  • Shares Outstanding, K 12,088
  • Annual Sales, $ 300 K
  • Annual Income, $ -8,240 K
  • 60-Month Beta 0.37
  • Price/Sales 73.80
  • Price/Cash Flow N/A
  • Price/Book 2.01
Trade PSTV with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +46.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7501 +7.42%
on 09/16/21
2.3000 -18.26%
on 09/02/21
-0.0400 (-2.08%)
since 08/16/21
3-Month
1.7501 +7.42%
on 09/16/21
2.9000 -35.17%
on 06/17/21
-0.8800 (-31.88%)
since 06/16/21
52-Week
1.7501 +7.42%
on 09/16/21
5.4200 -65.31%
on 02/10/21
-1.2600 (-40.13%)
since 09/16/20

Most Recent Stories

More News
Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Company's Chief Medical Officer

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced...

PSTV : 1.8800 (+1.62%)
Plus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced...

PSTV : 1.8800 (+1.62%)
Plus Therapeutics Announces Presentation of Data from the ReSPECT(TM)-GBM Trial and Plans for Treating Pediatric Brain Cancer

Data shows that the administration of Rhenium-186 NanoLiposome (RNL) via convection enhanced delivery for recurrent glioblastoma is well tolerated at significantly higher doses of radiotherapy than with...

PSTV : 1.8800 (+1.62%)
Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial

Positive data to support FDA IND application for the clinical evaluation of Rhenium-186 Nanoliposome (RNL) targeted radiotherapy for patients with leptomeningeal metastases (LM)

PSTV : 1.8800 (+1.62%)
Plus Therapeutics to Present Data from ReSPECT(TM)-GBM Trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult-to-treat cancers, today announced it will...

PSTV : 1.8800 (+1.62%)
Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult to treat cancers, today announced it will...

PSTV : 1.8800 (+1.62%)
Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement

Global agreement covers RNL manufacturing intermediate

PSTV : 1.8800 (+1.62%)
Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced...

PSTV : 1.8800 (+1.62%)
Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT(TM)-GBM Trial

Recurrent Glioblastoma Trial Update Planned for Q4 2021

PSTV : 1.8800 (+1.62%)
Plus Therapeutics to Announce Second Quarter 2021 Financial Results and Host Conference Call on July 22, 2021

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that...

PSTV : 1.8800 (+1.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Plus Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing treatments for cancer and other diseases primarily in the United States. The company's product candidate consists of DocePLUS which are in clinical stage. Plus Therapeutics Inc., formerly known as Cytori Therapeutics...

See More

Key Turning Points

3rd Resistance Point 2.0532
2nd Resistance Point 1.9666
1st Resistance Point 1.9233
Last Price 1.8800
1st Support Level 1.7934
2nd Support Level 1.7068
3rd Support Level 1.6635

See More

52-Week High 5.4200
Fibonacci 61.8% 4.0181
Fibonacci 50% 3.5851
Fibonacci 38.2% 3.1520
Last Price 1.8800
52-Week Low 1.7501

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar